Summary
Compiles FDA RWE framework guidance, RWD source evaluations, and published RWE submission precedents to support real-world evidence strategies in oncology.
Detailed Description
The Real-World Evidence Oncology Pack supports sponsors seeking to incorporate real-world evidence into oncology regulatory submissions. It aggregates the FDA's RWE framework, evaluations of real-world data sources, and precedent RWE submissions to help design regulatory-grade RWE studies.
The pack catalogs and evaluates RWD sources relevant to oncology, including electronic health records, claims databases, cancer registries, and genomic databases, assessing their fitness for use against FDA expectations. It analyzes successful and unsuccessful RWE submissions to identify the characteristics that determine regulatory acceptance.
Deliverables include an RWD source fitness-for-use assessment, an RWE study design aligned with the FDA framework, and a comparative analysis of RWE submissions in oncology with regulatory outcomes and lessons learned.
Evidence Sources
| Source | Type | Description | Refresh |
|---|---|---|---|
| FDA RWE Framework | REGULATORY | FDA framework for real-world evidence including guidance on study design, data standards, and submission requirements | Monthly |
| RWD Source Catalog | CURATED | Curated catalog of real-world data sources with quality assessments, coverage characteristics, and oncology relevance | Quarterly |
| Published RWE Submissions | REGULATORY | Database of FDA submissions incorporating RWE with regulatory outcomes and review documents | Monthly |
Regulatory Mapping
Real-World Data: Assessing Electronic Health Records and Medical Claims Data To Support Regulatory Decision-Making for Drug and Biological Products
General Principles on Plan, Design, and Analysis of Pharmacoepidemiological Studies That Utilize Real-World Data
Real-World Data: Assessing Registries to Support Regulatory Decision-Making for Drug and Biological Products
Agent Transparency
When you run this pack, your request is processed by a pipeline of specialized AI agents. Each agent operates with a defined confidence threshold and is auditable end-to-end.
Evidence Retriever
brew-retriever-v3
Queries curated sources for relevant evidence objects. Searches across regulatory databases, clinical registries, and scientific literature to surface the most pertinent references for the pack domain.
Domain Analyzer
brew-domain-analyst-v2
Applies domain-specific reasoning and regulatory mapping. Interprets evidence in the context of FDA, ICH, and EMA frameworks and tags each finding with the relevant guidance references.
Evidence Synthesizer
brew-synthesizer-v2
Synthesizes findings into structured output. Combines retrieved evidence and domain analysis into a cohesive narrative with quantitative summaries, comparative tables, and actionable recommendations.
Output Validator
brew-validator-v1
Validates citations, checks confidence thresholds, and ensures all referenced sources are accessible and correctly attributed. Flags any claims that fall below the confidence floor.
Sample Outputs
RWD Source Fitness Assessment
PDFEvaluation of candidate real-world data sources against FDA fitness-for-use criteria
RWE Study Design Protocol
PDFStudy design and statistical analysis plan for a regulatory-grade RWE study aligned with FDA framework
RWE Submission Precedent Analysis
XLSXComparative analysis of RWE submissions in oncology with regulatory outcomes and success factors
Deliverables included
- RWD source fitness-for-use assessment
- RWE study protocol aligned with FDA framework
- External control arm feasibility analysis
- RWE submission precedent analysis with lessons learned
- Data governance and quality framework
Related Disease & Biomarker Mappings
| Therapeutic Area | Disease Family | Key Biomarkers | Relevance |
|---|---|---|---|
| Solid Tumors | Non-Small Cell Lung Cancer | EGFRALKPD-L1KRAS G12C | Primary |
| Solid Tumors | Breast Cancer | HER2ER/PRBRCA1/2PIK3CA | Primary |
| Hematologic Malignancies | Acute Myeloid Leukemia | FLT3-ITDIDH1/2NPM1 | Secondary |
| Solid Tumors | Colorectal Cancer | KRAS/NRASBRAF V600EMSI-H/dMMR | Secondary |
Related Packs in Oncology
Oncology Trial Design Pack
Design smarter trials with real-world precedent data
Dose Optimization Pack (Project Optimus)
Navigate the new dose optimization paradigm with confidence
Biomarker-Driven Trial Design Pack
Turn molecular insights into registration-ready trial designs
Immuno-Oncology Combination Pack
Build the regulatory case for your IO combination
Version History
Current release — expanded evidence sources, improved citation accuracy, and added new regulatory cross-references.
Beta release — validated with domain SMEs. Added sample output previews and refined confidence scoring.
Initial draft — core evidence retrieval pipeline and output schema established.
Need a Custom Evidence Pack?
Our enterprise team can build bespoke evidence packs tailored to your therapeutic area, regulatory strategy, or internal decision framework. Custom packs include dedicated evidence source curation, domain-specific agent tuning, and priority SLA support.
Enterprise packs are available for organizations on the BrewBio Pro or Enterprise plan.